AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data

 
• By Alaric DeArment
  
AstraZeneca and Merck are closer to snagging a first-line prostate cancer label for Lynparza • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category